FDA OOPD grants orphan drug designation to Alitair’s Erdosteine for treatment of bronchiectasis

Alitair Pharmaceuticals, Inc., today announced that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has granted orphan drug designation for its drug candidate, Erdosteine®, for the treatment of bronchiectasis. Erdosteine is a mucolytic with antibacterial, anti-inflammatory, and antioxidant properties. Alitair President and CEO William Howard said, "We are excited

Bronchiectasis Awareness

Bronchiectasis Awareness poster If you could help us raise awareness of Bronchiectasis by downloading the Bronchiectasis Awareness poster and posting in surgeries and clinics. We can get the message out to look for the symptoms of Bronchiectasis. Many of our community are failing to be diagnosed and misdiagnosed with another respiratory condition.

Danielle’s story

My story, Danielle Hudson When I was 18 months old I had a chest infection that turned to double pneumonia and I was in an oxygen tent for 4 days. The antibiotics I was given at this time, tetracycline, left my teeth discoloured. I was in hospital for a year, which was fairly typical for